Improved survival with screening for hepatocellular carcinoma

Area of Science:

• Hepatobiliary Medicine
• Oncology
• Public Health

Background:

• Hepatocellular cancer (HCC) is a leading cause of cancer mortality globally.
• Existing screening programs in Asian nations show success, but their utility in the U.S. remains uncertain.
• Hawaii's predominantly Asian population presents a unique demographic for studying HCC screening efficacy.

Purpose of the Study:

• To evaluate the impact of screening on survival rates for hepatocellular cancer (HCC).
• To assess whether early detection through screening improves outcomes in a predominantly Asian population in Hawaii.

Main Methods:

• Retrospective review of 91 HCC cases diagnosed between 1993 and 1998.
• Patients categorized into symptomatic (S), asymptomatic (A), and asymptomatic but screened (A/Sc) groups.
• Kaplan-Meier analysis used to compare overall survival across the three patient groups.

Main Results:

• Patients in the asymptomatic and screened group (A/Sc) demonstrated significantly longer survival (median 1,399 days) compared to the symptomatic group (S) (median 234 days; P =.009).
• The asymptomatic but unscreened group (A) had a median survival of 545 days, not significantly different from other groups.
• Early detection via screening in asymptomatic individuals correlated with improved HCC survival outcomes.

Conclusions:

• Screening for hepatocellular cancer (HCC) in asymptomatic individuals is associated with significantly increased survival.
• Findings support the potential implementation of a formal HCC screening program in Hawaii.
• Prospective studies are recommended to confirm these survival benefits and optimize screening strategies.